DK2752428T3 - Humanisering af kanin-antistoffer under anvendelse af et universelt antistof-framework - Google Patents

Humanisering af kanin-antistoffer under anvendelse af et universelt antistof-framework Download PDF

Info

Publication number
DK2752428T3
DK2752428T3 DK14162664.8T DK14162664T DK2752428T3 DK 2752428 T3 DK2752428 T3 DK 2752428T3 DK 14162664 T DK14162664 T DK 14162664T DK 2752428 T3 DK2752428 T3 DK 2752428T3
Authority
DK
Denmark
Prior art keywords
humanization
antibody framework
rabbit antibodies
universal antibody
universal
Prior art date
Application number
DK14162664.8T
Other languages
English (en)
Inventor
Leonardo Borras
David Urech
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK2752428T3 publication Critical patent/DK2752428T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK14162664.8T 2008-06-25 2009-06-25 Humanisering af kanin-antistoffer under anvendelse af et universelt antistof-framework DK2752428T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US7569208P 2008-06-25 2008-06-25
US7569708P 2008-06-25 2008-06-25
US15510509P 2009-02-24 2009-02-24
US15504109P 2009-02-24 2009-02-24
CH8322009 2009-06-02
EP09768695.0A EP2307458B1 (en) 2008-06-25 2009-06-25 Humanization of rabbit antibodies using a universal antibody framework

Publications (1)

Publication Number Publication Date
DK2752428T3 true DK2752428T3 (da) 2020-02-24

Family

ID=43414179

Family Applications (3)

Application Number Title Priority Date Filing Date
DK09768695.0T DK2307458T3 (da) 2008-06-25 2009-06-25 Humanisering af kanin-antistoffer under anvendelse af en universel antistof-ramme
DK19208570.2T DK3628686T3 (da) 2008-06-25 2009-06-25 Humanisering af kanin-antistoffer under anvendelse af et universelt antistof-framework
DK14162664.8T DK2752428T3 (da) 2008-06-25 2009-06-25 Humanisering af kanin-antistoffer under anvendelse af et universelt antistof-framework

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK09768695.0T DK2307458T3 (da) 2008-06-25 2009-06-25 Humanisering af kanin-antistoffer under anvendelse af en universel antistof-ramme
DK19208570.2T DK3628686T3 (da) 2008-06-25 2009-06-25 Humanisering af kanin-antistoffer under anvendelse af et universelt antistof-framework

Country Status (16)

Country Link
US (5) US8293235B2 (da)
EP (3) EP2752428B8 (da)
JP (1) JP5856480B2 (da)
KR (4) KR101834797B1 (da)
CN (3) CN104004094B (da)
AU (4) AU2009264567B2 (da)
BR (1) BRPI0914663A2 (da)
DK (3) DK2307458T3 (da)
ES (1) ES2677003T3 (da)
HU (1) HUE038432T2 (da)
MX (1) MX345395B (da)
PL (2) PL2307458T3 (da)
RU (1) RU2635186C2 (da)
SI (2) SI2752428T1 (da)
TR (1) TR201808591T4 (da)
WO (1) WO2009155726A2 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2259795B1 (en) * 2008-03-26 2016-04-06 Epitomics, Inc. Anti-vegf antibody
TR201808591T4 (tr) * 2008-06-25 2018-07-23 Esbatech Alcon Biomed Res Unit Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması.
BRPI0914319B8 (pt) 2008-06-25 2021-05-25 Esbatech Alcon Biomed Res Unit imunoligante que se liga especificamente ao tnf alfa humano e composição
CA3020290A1 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
WO2010003268A2 (en) * 2008-07-10 2010-01-14 Esbatech, An Alcon Biomedical Research Unit Llc Methods and compositions for enhanced delivery of macromolecules
JP5764071B2 (ja) 2009-02-24 2015-08-12 エスバテック − ア ノバルティスカンパニー エルエルシー 細胞表面抗原のイムノバインダーを同定するための方法
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
AU2014262201B2 (en) * 2009-12-23 2016-09-15 Novartis Ag Method for decreasing immunogenicity
JP5914353B2 (ja) 2009-12-23 2016-05-11 エスバテック − ア ノバルティス カンパニー エルエルシー 免疫原性を減少させるための方法
CA2795734A1 (en) * 2010-04-07 2011-10-13 Abbvie Inc. Tnf-.alpha. binding proteins
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
UY34404A (es) 2011-10-20 2013-05-31 Esbatech A Novartis Co Llc Anticuerpo estable unido a múltiples antígenos
KR102069394B1 (ko) * 2011-11-23 2020-01-22 에프. 호프만-라 로슈 아게 Cd40l 발현 포유류 세포 및 그의 용도
EP2914287B1 (en) 2012-11-05 2020-03-18 Delenex Therapeutics AG Binding members to il-1 beta
WO2014095808A1 (en) 2012-12-17 2014-06-26 Delenex Therapeutics Ag Antibodies against il-1 beta
EP2956478A1 (en) * 2013-02-15 2015-12-23 ESBATech - a Novartis Company LLC Acceptor framework for cdr grafting
CN104884471A (zh) * 2013-02-20 2015-09-02 艾斯巴技术-诺华有限责任公司 用于cdr移植的受体框架
WO2014206561A1 (en) 2013-06-26 2014-12-31 Numab Ag Novel antibody frameworks
EP3026060A1 (en) 2014-11-26 2016-06-01 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for CD45R0
EP3283512A4 (en) * 2015-04-17 2018-10-03 Distributed Bio Inc Method for mass humanization of non-human antibodies
CA2988001C (en) 2015-04-30 2023-09-26 Abcheck S.R.O. Method for mass humanization of rabbit antibodies
AU2017224843A1 (en) 2016-02-25 2018-08-23 Cell Medica Switzerland Ag Binding members to PD-L1
EP3219726B1 (en) 2016-03-17 2020-12-02 Tillotts Pharma AG Anti-tnf alpha-antibodies and functional fragments thereof
SI3219727T1 (sl) 2016-03-17 2021-04-30 Tillotts Pharma Ag Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
IL261098B1 (en) 2016-03-17 2024-05-01 Numab Therapeutics AG Antibodies against TNF-ALPHA and their functional fragments
CN108884156B (zh) 2016-03-17 2021-10-01 努玛创新有限公司 抗TNFα抗体及其功能片段
CA3016870A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag Anti-tnf.alpha.-antibodies and functional fragments thereof
EP3409688A1 (en) 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
EP3456739A1 (en) 2017-09-19 2019-03-20 Tillotts Pharma Ag Use of anti-tnfalpha antibodies for treating wounds
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
ES2938608T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
EP3459528B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
JP2021525779A (ja) * 2018-06-08 2021-09-27 ヴェンタナ メディカル システムズ, インク. 機能性および製造可能性を改善するための普遍的なまたは正規化された抗体フレームワーク
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
JOP20210152A1 (ar) 2018-12-18 2023-01-30 Novartis Ag صياغة محلول بروتيني محتوية على تركيز عالٍ من جسم مضاد لـ vegf
JP2022523908A (ja) 2019-01-31 2022-04-27 ヌマブ セラピューティクス アクチェンゲゼルシャフト TNFα及びIL-17Aに対する特異性を有する多重特異性抗体、IL-17Aを標的とする抗体、及びそれらの使用方法
CN116848136A (zh) 2021-02-12 2023-10-03 勃林格殷格翰国际有限公司 补体c3抗原结合蛋白
KR20230169944A (ko) 2021-03-09 2023-12-18 씨디알-라이프 아게 Mage-a4 펩티드-mhc 항원 결합 단백질
WO2022190007A1 (en) 2021-03-09 2022-09-15 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries
WO2023110918A1 (en) 2021-12-14 2023-06-22 Cdr-Life Ag Dual mhc-targeting t cell engager
WO2024056758A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0832981A1 (en) * 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DK0590058T3 (da) * 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
EP0627932B1 (en) * 1992-11-04 2002-05-08 City Of Hope Antibody construct
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ATE253593T1 (de) * 1996-07-16 2003-11-15 Plueckthun Andreas Prof Dr Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
US6905668B1 (en) 1998-09-25 2005-06-14 Tokyo Gas Company Limited Diagnostic agents for pancreatic exocrine function
AU1102401A (en) * 1999-10-22 2001-05-08 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products
CA2396534C (en) 1999-12-28 2012-10-02 Esbatech Ag Intrabodies with defined framework that is stable in a reducing environment and applications thereof
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
WO2002002781A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
AU3942202A (en) * 2000-11-30 2002-06-11 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
JP2004519233A (ja) 2001-02-19 2004-07-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 免疫原性の低減された修飾された抗egfr抗体
GB0110029D0 (en) * 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
NZ536412A (en) 2002-05-22 2008-10-31 Esbatech Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
US20040086979A1 (en) 2002-08-15 2004-05-06 Dongxiao Zhang Humanized rabbit antibodies
EP1561107A1 (en) * 2002-11-13 2005-08-10 Micromet AG Method for identifying antigen specific b cells
DE10314412A1 (de) 2003-03-28 2004-10-14 Genovac Ag Genetische Immunisierung mit multiplen Expressionskonstrukten zur Herstellung von monoklonalen Antikörpern
WO2004108721A1 (en) 2003-04-01 2004-12-16 Sun Pharmaceutical Industries Limited Process for the preparation of 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl] methyl]-2,4-thiazolidinedione
US20050048578A1 (en) * 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
SG128680A1 (en) 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
WO2005016950A1 (en) 2003-08-07 2005-02-24 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
CA2537055A1 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
US7569708B2 (en) 2003-11-20 2009-08-04 Mitsubishi Gas Chemical Company, Inc. Liquid cyclohexane-tricarboxylic acid anhydride
US20080003617A1 (en) 2004-12-20 2008-01-03 Xiaomin Fan Methods for the identification and the isolation of epitope specific antibodies
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
EP1891110A2 (en) * 2005-06-07 2008-02-27 Esbatech AG STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha
AU2006262603B2 (en) * 2005-06-20 2011-01-06 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7429487B2 (en) * 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
GB0520436D0 (en) * 2005-10-07 2005-11-16 Photobiotics Ltd Biological materials and uses thereof
WO2007042809A2 (en) * 2005-10-11 2007-04-19 Domantis Limited Antibody polypeptide library screening and selected antibody polypeptides
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
KR101457228B1 (ko) * 2006-04-28 2014-11-04 델레넥스 쎄라퓨틱스 아게 수용체 티로신 키나제 alk의 세포외 도메인에 결합하는 항체
CA2652945C (en) * 2006-05-30 2015-06-02 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
WO2008004834A1 (en) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
AU2007272224B2 (en) * 2006-07-10 2013-05-02 Novartis Ag scFv antibodies which pass epithelial and/or endothelial layers
US7552970B2 (en) 2006-07-11 2009-06-30 La-Z-Boy Incorporated Furniture mechanism with tilt cam for multiple position tilt
EP3202786A3 (en) 2007-03-12 2017-10-11 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
CA2681530C (en) * 2007-03-22 2017-03-28 Biogen Idec Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154
AU2008254578B2 (en) 2007-05-21 2013-06-06 Alderbio Holdings Llc Novel rabbit antibody humanization methods and humanized rabbit antibodies
CN103435696B (zh) 2007-06-25 2016-10-12 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
CN101688200B (zh) 2007-06-25 2012-08-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的改造和优化
CA3020290A1 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
BRPI0914319B8 (pt) * 2008-06-25 2021-05-25 Esbatech Alcon Biomed Res Unit imunoligante que se liga especificamente ao tnf alfa humano e composição
TR201808591T4 (tr) 2008-06-25 2018-07-23 Esbatech Alcon Biomed Res Unit Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması.
JP5745720B2 (ja) 2008-06-25 2015-07-08 エスバテック − ア ノバルティスカンパニー エルエルシー イムノバインダーの溶解性の最適化
JP5764071B2 (ja) * 2009-02-24 2015-08-12 エスバテック − ア ノバルティスカンパニー エルエルシー 細胞表面抗原のイムノバインダーを同定するための方法
JP5914353B2 (ja) * 2009-12-23 2016-05-11 エスバテック − ア ノバルティス カンパニー エルエルシー 免疫原性を減少させるための方法
AR083495A1 (es) * 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
EP2760855B1 (en) * 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
EP3765083A1 (en) 2018-03-16 2021-01-20 Novartis Ag Methods for treating ocular diseases
JOP20210152A1 (ar) 2018-12-18 2023-01-30 Novartis Ag صياغة محلول بروتيني محتوية على تركيز عالٍ من جسم مضاد لـ vegf

Also Published As

Publication number Publication date
KR20160085374A (ko) 2016-07-15
EP2752428B9 (en) 2020-01-22
EP2307458B1 (en) 2018-04-11
PL2752428T3 (pl) 2020-05-18
AU2018200640B2 (en) 2019-11-21
US10087244B2 (en) 2018-10-02
BRPI0914663A2 (pt) 2015-10-20
KR101882352B1 (ko) 2018-07-26
JP5856480B2 (ja) 2016-02-09
CN102164958A (zh) 2011-08-24
TR201808591T4 (tr) 2018-07-23
EP2752428B1 (en) 2019-11-13
KR20160022398A (ko) 2016-02-29
EP3628686A1 (en) 2020-04-01
EP2307458A2 (en) 2011-04-13
DK2307458T3 (da) 2018-07-16
KR20110022715A (ko) 2011-03-07
AU2016201023A1 (en) 2016-03-10
AU2009264567A1 (en) 2009-12-30
AU2009264567B2 (en) 2014-06-12
KR20180085834A (ko) 2018-07-27
EP2752428A1 (en) 2014-07-09
US8937162B2 (en) 2015-01-20
HUE038432T2 (hu) 2018-10-29
CN104004094B (zh) 2017-09-22
KR101834797B1 (ko) 2018-03-07
SI2752428T1 (sl) 2020-03-31
US11858981B2 (en) 2024-01-02
ES2677003T3 (es) 2018-07-27
KR102007492B1 (ko) 2019-08-05
DK3628686T3 (da) 2021-09-06
PL2307458T3 (pl) 2018-08-31
CN104004094A (zh) 2014-08-27
AU2016201023B2 (en) 2017-10-26
AU2014203813B2 (en) 2015-12-03
MX345395B (es) 2017-01-30
US20160096903A1 (en) 2016-04-07
SI2307458T1 (en) 2018-08-31
RU2635186C2 (ru) 2017-11-09
KR101956059B1 (ko) 2019-03-08
US20130023652A1 (en) 2013-01-24
WO2009155726A2 (en) 2009-12-30
RU2016103262A (ru) 2017-08-03
EP2752428B8 (en) 2020-02-26
JP2011525360A (ja) 2011-09-22
US9593161B2 (en) 2017-03-14
US20140221624A1 (en) 2014-08-07
CN107090035A (zh) 2017-08-25
WO2009155726A3 (en) 2010-07-15
US20180127493A1 (en) 2018-05-10
EP3628686B1 (en) 2021-07-21
US8293235B2 (en) 2012-10-23
AU2014203813A1 (en) 2014-07-31
US20110117091A1 (en) 2011-05-19
AU2018200640A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
DK3628686T3 (da) Humanisering af kanin-antistoffer under anvendelse af et universelt antistof-framework
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
SMT201700083B (it) Anticorpi monoclonali
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
BRPI0809677A2 (pt) Anticorpos anti-ige
BRPI0821777A2 (pt) Anticorpos biespecíficos bivalentes
DK2131860T3 (da) Anti-sclerostin-antistoffer
NO344963B1 (no) Humanisert antistoff
BRPI0819165A2 (pt) Anticorpos anti-vegf
CR20170001A (es) Anticuerpos anti factor d humanizados
BRPI0916915A2 (pt) anticorpos anti-il-17a/f de reatividade cruzada e biespecíficos
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
DK2459167T3 (da) SUBKUTAN ANTI-HER2-antistofformulering
BRPI0907237A2 (pt) Anticorpo anti-cldn6
DK2521736T3 (da) Humaniserede antistoffer
DK2044121T3 (da) Glyco-konstruerede antistoffer
BRPI0822447A2 (pt) Anticorpo monoclonal e método do mesmo
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
DK2238166T3 (da) Anvendelse af et anti-amyloid-beta-antistof ved øjensygdomme
DK2531526T3 (da) Fremgangsmåde til opnåelse af antistoffer
BRPI0909633A2 (pt) anticorpos anti-tyrp1
BR112012025082A2 (pt) novos anticorpos monoclonais e método de análise imunológica de dímero-d
BRPI0912769A2 (pt) anticorpos anti-pirb
DK2094728T3 (da) Fremgangsmåder til anvendelse for human-adapterende monoklonale antistoffer
DK2202307T3 (da) Fremgangsmåde til fremstiling af et antistof